$1.35 +0.05 (3.85%) RXi Pharmaceuticals Corp - NASDAQ

Dec. 5, 2016 | 04:00 PM

Quotes

  1. Quotes

  2. Charts

  3. Analysis

  4. Options

  5. Historical



Last Trade: 1.35
Trade Time: Dec 05 04:00 PM Eastern Daylight Time
Change: +0.05 (3.85%)
Prev Close: 1.30
Open: 1.30
Bid: 1.34
Ask: 1.36
  1. No results found.
  1. RXi Pharmaceuticals Announces Remarkable and Positive Results with its Novel Self-Delivering RNAi Platform: Potent Reduction of Long Non-coding RNAs Demonstrated in Collaboration with Biogazelle

    Benzinga | Oct. 20, 2015 | 06:03AM EST
  2. RXi Pharmaceuticals Announces Positive Interim Results in Phase 2a Dermatology Program with RXI-109

    Benzinga | Oct. 15, 2015 | 06:02AM EST
  3. RXi Pharmaceuticals Bolsters Protection for its Novel Self-Delivering RNAi Platform with Notice of Allowance from USPTO

    Benzinga | Oct. 5, 2015 | 06:03AM EST
  4. RXi Pharmaceuticals Granted Patent in China for Lead Clinical Candidate RXI-109

    Benzinga | Sep. 28, 2015 | 06:03AM EST
  5. RXi Pharmaceuticals Announces Proposed Public Offering of Common Stock and Warrants

    Benzinga | May. 27, 2015 | 15:19PM EST
  6. RXI Pharma Announces Expansion of Clinical Pipeline with Exclusive License for Second Phase 2 Clinical Compound

    Benzinga | Dec. 19, 2014 | 07:06AM EST
  7. RXi Pharmaceuticals To Present New Data In Its First Phase 2a Clinical Trial With RXI-109

    Benzinga | Oct. 7, 2014 | 06:04AM EST
  8. RXi Pharmaceuticals Appoints Peter Campochiaro M.D. To Its Scientific Advisory Board

    Benzinga | Jul. 7, 2014 | 06:03AM EST
  9. RXi Pharmaceuticals to Present at ARVO 2014 Annual Meeting

    Benzinga | Apr. 28, 2014 | 06:06AM EST
  10. RXi Pharmaceuticals Initiates First Phase 2 Study with RXI-109

    Benzinga | Nov. 13, 2013 | 07:06AM EST
  11. RXi Pharmaceuticals Announces Completion of Dosing in Phase 1 Trial for RXI-109 Program

    Benzinga | Sep. 24, 2012 | 00:09AM EST
Trading Center